Scarica l'app Stockscreener
232.36
0.03%
0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever. - The Motley Fool
How higher bond yields impact AbbVie Inc. stockTrade Volume Summary & Fast Exit and Entry Trade Guides - newser.com
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer - Investing News Network
Mubadala Investment Co PJSC reports share stake in Adobe, Verizon, dissolves in RTX, AbbVie - MarketScreener
Is AbbVie Inc 4AB a good long term investmentExit Strategy Tips & Discover High-Return Stocks Before They Boom - earlytimes.in
Will AbbVie Inc. stock announce special dividendJuly 2025 Fed Impact & High Yield Stock Recommendations - newser.com
AbbVie exits $1.5 billion longevity drug deal with Calico: report - Crain's Chicago Business
Is AbbVie Inc. (4AB) stock a buy before earnings resultsMarket Weekly Review & Intraday High Probability Setup Alerts - newser.com
Can AbbVie Inc. stock sustain revenue growthEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
The Fight to Save the $2.7 Billion Botox Empire - Bloomberg.com
Is AbbVie Inc. stock undervalued vs historical averages2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Why AbbVie Inc. (4AB) stock stays on top picksWeekly Stock Summary & Consistent Income Trade Recommendations - newser.com
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth - The Manila Times
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic - GlobeNewswire
How AbbVie Inc. (Common Stock) (4AB0) stock performs during market turbulenceJobs Report & High Accuracy Trade Alerts - newser.com
Argus Raises AbbVie's Price Target to $250 From $220 - MarketScreener
Can momentum traders help lift AbbVie Inc.IPO Watch & Consistent Growth Stock Picks - newser.com
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award - Investing News Network
Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More - MSN
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+ - BioSpace
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™ - Yahoo Finance
AbbVie exits alliance with Alphabet biotech Calico; report - pharmaphorum
Chiesi licenses AbbVie subsidiary's BBB platform - The Pharma Letter
Scotiabank Initiates AbbVie at Sector Outperform With $280 Price Target - MarketScreener
How AbbVie Inc. stock trades before earningsTrade Performance Summary & Community Verified Watchlist Alerts - newser.com
Here Are Thursday's Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More - 24/7 Wall St.
AbbVie and Calico end groundbreaking partnership after 11 years without an approved drug - The Business Journals
Why AbbVie Inc. stock appears on watchlistsJuly 2025 Momentum & Stepwise Entry/Exit Trade Alerts - newser.com
Can AbbVie Inc. (Common Stock) (4AB0) stock retain market dominancePortfolio Gains Summary & Technical Pattern Alert System - newser.com
AbbVie Shares Rise To Intraday High After Key Trading Signal - Benzinga
AbbVie Reportedly Ends Partnership With Alphabet-Backed Calico Life Sciences - Stocktwits
How reliable is AbbVie Inc. (4AB) stock dividend growthWeekly Profit Summary & Low Risk High Win Rate Picks - newser.com
AbbVie (ABBV) Ends R&D Partnership with Calico Life Sciences - GuruFocus
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance? - Yahoo Finance
AbbVie reportedly ending R&D deal with Alphabet-backed antiaging firm Calico - Seeking Alpha
AbbVie Severs Ties With Google-Backed Aging Research Biotech - MarketScreener
AbbVie cuts ties with Google-backed longevity company, lays off scientists - statnews.com
AbbVie (ABBV) Surged Following Strong Results and Increased Guidance - Insider Monkey
How AbbVie Inc. (4AB) stock benefits from digital adoptionShort Setup & Daily Technical Forecast Reports - newser.com
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders - The Manila Times
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence - AbbVie News Center
Daiwa Securities Adjusts Price Target on AbbVie to $226 From $214, Maintains Outperform Rating - MarketScreener
Fund Update: 81,625 ABBVIE (ABBV) shares added to THORNBURG INVESTMENT MANAGEMENT INC portfolio - Quiver Quantitative
AbbVie Has Many Bullish Attributes (Technical Analysis) - Seeking Alpha
Is AbbVie Inc. (4AB) stock undervalued after correctionSell Signal & Safe Entry Trade Reports - newser.com
Is AbbVie Inc. stock undervalued at current price2025 Price Action Summary & Community Driven Trade Alerts - newser.com
Ironwood surges after Q3 beat; raised outlook for AbbVie-partnered Linzess - MSN
Ironwood raises outlook for AbbVie's Linzess (IRWD:NASDAQ) - Seeking Alpha
How Analyst Views Are Shaping the Evolving Story for AbbVie - Yahoo Finance
Is AbbVie's (ABBV) Dividend Hike Amid Margin Pressures Shaping Its Investment Appeal? - Yahoo Finance
Can AbbVie Inc. stock retain market dominanceBear Alert & Fast Gain Swing Alerts - newser.com
Is AbbVie Inc. reversing from oversold territoryJuly 2025 Review & Technical Pattern Recognition Alerts - newser.com
How AbbVie Inc. stock performs in rising dollar environmentDay Trade & Weekly Market Pulse Updates - newser.com
0.35%
0.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):